Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 pathway

Clinical Reviews in Bone and Mineral Metabolism

Volumn 3, Issue 3-4, 2005, Pages 189-193

  Kaplan, Frederick S ^a   Shore, Eileen M ^a   Gupta, Rishi ^a   Billings, Paul C ^a   Glaser, David L ^a   Pignolo, Robert J ^a   Graf, Daniel ^b   Kamoun, Malek ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

Autoimmunity; Bone morphogenic protein (BMP)4 signaling pathway; Fibrodysplasia ossificans progressiva (FOP); Immune system

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; OSSIFYING MYOSITIS; PROTEIN DEFECT; REVIEW; SIGNAL TRANSDUCTION;

EID: 25844469044     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/BMM:3:3-4:189     Document Type: Review

References (51)

1. Kaplan FS, Shore EM, Connor JM. 2002 Fibrodysplasia ossificans progressiva (FOP). In: Royce PM, Steinmann B, eds. Connective Tissue and Its Heritable Disorders: Molecular, Genetic, and Medical Aspects, 2nd Ed. Wiley-Liss; John Wiley & Sons, New York, pp. 827-840.
2. Kaplan FS, Glaser, DL, Hebela N, Shore EM. 2004 Heterotopic ossification. J Am Acad Orthop Surg 12:116-125.
3. Shafritz AB, Shore EM, Gannon FH, et al. 1996 Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 335:555-561.
4. Ahn J, Serrano de la Peña L, Shore EM, Kaplan FS. 2003 Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J Bone Joint Surg Am 85:667-674.
5. Olmsted EA, Kaplan FS, Shore EM. 2003 Bone morphogenetic protein 4 regulation in fibrodysplasia ossificans progressiva. Clin Orthop 408:331-343.
6. Gannon FH, Kaplan FS, Olmsted E, Finkel G, Zasloff MA, Shore EM. 1997 Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum Pathol 28:339-343.
7. Glaser DL, Economides AN, Wang L, et al. 2003 In vivo somatic cell gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am 85:2332-2342.
8. Kan, L, Hu M, Gomes WA, Kessler JA. 2004 Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Pathol 165:1107-1115.
9. Serrano de la Peña L, Billings PC, Fiori JL, Ahn J, Kaplan FS, Shore EM. 2005 Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J Bone Miner Res 20:1168-1176.
10. Davidson A, Diamond B. 2001 Autoimmune diseases. N Engl J Med 345:340-350.
11. Marrack P, Kappler J, Kotzin BL. 2001 Autoimmune disease: why and where it occurs. Nat Med 7:899-905.
12. Rosen A, Casciola-Rosen L. 2001 Clearing the way to mechanisms of autoimmunity. Nat Med 7:664-665.
13. Shlomchik MJ, Craft JE, Mamula MJ. 2001 From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2:147-153.
14. Cohen RB, Hahn GV, Tabas J, et al. 1993 The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 75:215-219.
15. Lanchoney TF, Cohen RB, Rocke DM, Zasloff MA, Kaplan FS. 1995 Permanent heterotopic ossification at the injection site after diphtheria-tetanus- pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatrics 126:762-764.
16. Luchetti W, Cohen RB, Hahn GV, et al. 1996 Severe restriction in jaw movement after route injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81:21-25.
17. Scarlett RF, Rocke DM, Kantanie S, Patel JB, Shore EM, Kaplan FS. 2004 Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva (FOP). Clin Orthop 423:275-279.
18. Moriatis JM, Gannon FH, Shore EM, Bilker W, Zasloff MA, Kaplan FS. 1997 Limb swelling in patients who have fibrodysplasia ossificans progressiva. Clin Orthop 336:247-253.
19. Gannon FH, Valentine BA, Shore EM, Zasloff MA, Kaplan FS. 1998 Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin Orthop 346:19-25.
20. Gannon FH, Glaser D, Caron R, Thompson LD, Shore EM, Kaplan FS. 2001 Mast cell involvement in fibrodysplasia ossificans progressiva. Hum Pathol 32:842-848.
21. Hafler DA. 2004 Multiple Sclerosis. J Clin Invest 113:788-794.
22. Ahn J, Feldman G, Terry L, Shore EM, Kaplan FS. 2003 Exoneration of NF-κB dysregulation in fibrodysplasia ossificans progressiva (FOP). Clin Orthop 406:205-213.
23. Godin I, Cumano A. 2002 The hare and the tortoise: an embryonic hematopoietic race. Nat Rev Immunol 2:593-604.
24. Bhardwaj G, Murdoch B, Wu D, et al. 2001 Sonic hedgehog induces the proliferation of primary human hematopoietic cells via BMP regulation. Nat Immunol 2:172-180.
25. Zhang J, Niu C, Ye L, et al. 2003 Identification of the hematopoietic stem cell niche and control of the niche size. Nature 425:836-841.
26. Ohnemus S, Kanzler B, Jerome-Majewska LA, et al. 2002 Aortic arch and pharyngeal phenotype in the absence of BMP-dependent neural crest in the mouse. Mech Develop 119:127-135.
27. Bachiller D, Klingensmith J, Shneyder N, et al. 2003 The role of chordin/BMP signals in mammalian pharyngeal development and DiGeorge syndrome. Development 130:3567-3578.
28. Tsai PT, Lee RA, Wu H. 2003. BMP4 acts upstream of FGF in modulating thymic stroma and regulating thymopoiesis. Blood 102:3947-3953.
29. Graf D, Nethisinghe S, Palmer DB, Fisher AG, Merkenschlager M. 2002 The developmentally regulated expression of twisted gastrulation reveals a role for bone morphogenetic proteins in the control of T cell development. J Exp Med 196:163-171.
30. Hager-Theodorides AL, Outram SV, Shah DK, et al. 2003 Bone morphogenetic protein 2/4 signaling regulates early thymocyte differentiation. J Immunol 169:5496-5504.
31. Nosaka T, Morita S, Kitamura H, et al. 2003 Mammalian twisted gastrulation is essential for skeleto-lymphogenesis. Mol Cell Biol 23:2969-2980.
32. Takagi T, Harada J, Ishii S. 2001 Murine Schnurri-2 is required for positive selection of thymocytes. Nat Immunol 2:1048-1053.
33. Kimura MY, Hosokawa H, Yamashita M, et al. 2005 Regulation of T helper type 2 cell differentiation by murine Schnurri-2. J Exp Med 201:397-408.
34. Detmer K, Steele TA, Shoop, MA, Dannawi H. 1999 Lineage-restricted expression of bone morphogenetic protein genes in human hematopoietic cell lines. Blood Cells Mol Dis 25:310-323.
35. Ishisaki A, Yamato K, Hashimoto S, et al. 1999 Differential inhibition of Smad 6 and Smad 7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J Biol Chem 274:13,637-13,642.
36. Nakahara T, Tominaga K, Koseki T, et al. 2003 Growth/differentiation factor-5 induces growth arrest and apoptosis in mouse B lineage cells with modulation by Smad. Cell Signal 15:181-187.
37. Varas A, Hager-Theodorides AL, Sacedon R, Vicente A, Zapata AG, Crompton T. 2003. The role of morphogens in T-cell development. Trends Immunol 24:197-206.
38. Cunningham NS, Paralkar V, Reddi AH. 1992. Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor B1 mRNA expression. Proc Natl Acad Sci USA 89:11,740-11,744.
39. Pignolo RJ, Billings PC, Suda K, et al. 2004 Circulating osteogenic cells in heterotopic bone formation. J Bone Miner Res 19:S35.
40. Banchereau J, Steinman RM. 1998 Dendritic cells and the control of immunity. Nature 392:245-252.
41. Ulloa L, Doody J, Massagué J. 1999 Inhibition of transforming growth factor-beta/SMAD signaling by the interferon-gamma/STAT pathway. Nature 397:710-713.
42. Dougall WC, Glaccum M, Charrier K, et al. 1999 RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424.
43. Bommireddy R, Saxena V, Ormsby I, et al. 2003 TGF-B1 regulates lymphocyte homeostasis by preventing activation and subsequent apoptosis of peripheral lymphocytes. J Immunol 170:4612-4622.
44. Kulkarni AB, Huh C-G, Becker D, et al. 1993 Transforming growth factor-B 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90:770-774.
45. Shull MM, Ormsby I, Kier AB, et al. 1992 Targeted disruption of the mouse transforming growth factor-B1 gene results in multifocal inflammatory disease. Nature 359: 693-699.
46. Yaswen L, Kulkarni AB, Fredrickson T, et al. 1996 Autoimmune manifestations in the transforming growth factor-B1 knockout mouse. Blood 87:1439-1445
47. Waldner H, Collins M, Kuchroo VK. 2004 Activation of antigen-presenting cells by microbial products breaks self-tolerance and induces autoimmune disease. J Clin Invest 113:990-997.
48. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. 2002 Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature 416: 603-607.
49. Boule MW, Broughton C, MacKay F, Akira S, Marshak-Rothstein A, Ritkin IR. 2004 Toll-like receptor 9-dependent and independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 199:1631-1640.
50. Xiao C, Shim JH, Klüppel M, et al. 2003 Ecsit is required for BMP signaling and mesoderm formation during mouse embryogenesis. Genes Dev 17:2933-2949.
51. Moustakas A, Heldin CH. 2003 Ecsit-ement on the cross-roads of toll and BMP signal transduction. Genes Dev 17:2855-2859.